De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
IQV Overzicht aandelen
IQVIA Holdings Inc. levert geavanceerde analyses, technologische oplossingen en klinische onderzoeksdiensten aan de biowetenschappelijke industrie in Noord- en Zuid-Amerika, Europa, Afrika en Azië-Pacific.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
AI And ML Drive Revenue Uplift In Life Sciences And Healthcare Sectors
IQVIA Holdings Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$227.40 |
| 52 Week Hoogtepunt | US$261.73 |
| 52 Week Laag | US$167.42 |
| Bèta | 1.49 |
| 11 maand verandering | -8.61% |
| 3 maanden verandering | 9.27% |
| 1 Jaar Verandering | 14.95% |
| 33 jaar verandering | -6.73% |
| 5 jaar verandering | 56.95% |
| Verandering sinds IPO | 440.01% |
Recent nieuws en updates
IQVIA Holdings Inc.'s (NYSE:IQV) Business Is Trailing The Market But Its Shares Aren't
Sep 22
IQVIA Holdings Inc. (NYSE:IQV) Shares Could Be 38% Below Their Intrinsic Value Estimate
Sep 08Reiterating Buy On IQVIA After Q2 Earnings
Aug 20With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 11Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Jul 30Recent updates
IQVIA Holdings Inc.'s (NYSE:IQV) Business Is Trailing The Market But Its Shares Aren't
Sep 22IQVIA Holdings Inc. (NYSE:IQV) Shares Could Be 38% Below Their Intrinsic Value Estimate
Sep 08Reiterating Buy On IQVIA After Q2 Earnings
Aug 20With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 11Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Jul 30These 4 Measures Indicate That IQVIA Holdings (NYSE:IQV) Is Using Debt Reasonably Well
Jul 18An Intrinsic Calculation For IQVIA Holdings Inc. (NYSE:IQV) Suggests It's 33% Undervalued
Jun 04IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
May 27Is It Time To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)?
Apr 24Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14IQVIA Holdings: Strong Q4 Results Suggest A Bullish 2024
Feb 22Is IQVIA Holdings Inc. (NYSE:IQV) Trading At A 29% Discount?
Jan 23Market Participants Recognise IQVIA Holdings Inc.'s (NYSE:IQV) Earnings
Dec 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Dec 08Should You Investigate IQVIA Holdings Inc. (NYSE:IQV) At US$205?
Nov 23IQVIA Q3: TAS Segment Remains The Problem Child
Nov 21IQVIA: I Would Stay Away Until Debt Issues Are Resolved
Nov 12Is There An Opportunity With IQVIA Holdings Inc.'s (NYSE:IQV) 32% Undervaluation?
Oct 08IQVIA: Stock To Remain Rangebound As I Expect Weak Numbers In The Near Term
Sep 07Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
Sep 04Why IQVIA Holdings Inc. (NYSE:IQV) Could Be Worth Watching
Aug 11IQVIA Holdings Q2: Breaking Ground And Beating Expectations
Aug 03IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 43% Above Its Share Price
Jun 27IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet
Jun 05IQVIA Holdings: A Possible Beat And Raise Scenario In The Works
May 23What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
May 04A Look At The Fair Value Of IQVIA Holdings Inc. (NYSE:IQV)
Mar 19Does IQVIA Holdings (NYSE:IQV) Have A Healthy Balance Sheet?
Mar 05Here's Why We Think IQVIA Holdings (NYSE:IQV) Might Deserve Your Attention Today
Feb 12IQVIA Q4 2022 Earnings Preview
Feb 09When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Jan 29IQVIA Holdings: Premium Valuation Is Justified For An Industry Leader
Jan 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Nov 09IQVIA Holdings Sees Digital Opportunities, But Debt Drags Growth
Nov 02IQVIA Q3 2022 Earnings Preview
Oct 25Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Oct 02IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)
Sep 19With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 22GSK, Iqvia launch Vaccine Track platform to highlight vaccine trends publicly in US
Aug 11We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Aug 08IQVIA: Resiliency And Quality Never Left, Q2 Earnings Evidence The Same
Jul 28Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 48%?
Jul 26IQVIA Non-GAAP EPS of $2.44 beats by $0.06, revenue of $3.54B beats by $50M, raises FY22 guidance
Jul 21IQVIA A Smart Choice In A High-Inflation Environment
Apr 29Rendement voor aandeelhouders
| IQV | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -3.7% | -2.5% | -0.7% |
| 1Y | 15.0% | 15.4% | 32.5% |
Rendement versus industrie: IQV presteerde slechter dan de US Life Sciences -sector, die het afgelopen jaar een rendement van 17.6 % opleverde.
Rendement versus markt: IQV presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.
Prijsvolatiliteit
| IQV volatility | |
|---|---|
| IQV Average Weekly Movement | 4.6% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: IQV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van IQV is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 88,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. houdt zich bezig met het leveren van geavanceerde analyses, technologische oplossingen en klinische onderzoeksdiensten aan de biowetenschappelijke industrie in Noord- en Zuid-Amerika, Europa, Afrika en Azië-Pacific. Het bedrijf is actief in drie segmenten: Technology & Analytics Solutions, Research & Development Solutions, en Contract Sales & Medical Solutions. Het segment Technology & Analytics Solutions biedt een scala aan cloud-gebaseerde toepassingen en bijbehorende implementatiediensten; real world oplossingen waarmee klanten in de biowetenschappen en de zorgsector bewijsmateriaal kunnen genereren en verspreiden, waardoor besluitvorming in de gezondheidszorg mogelijk wordt en de resultaten voor patiënten verbeteren; en strategische en implementatie adviesdiensten, zoals geavanceerde analytics en outsourcing van commerciële processen.
IQVIA Holdings Inc. Samenvatting
| IQV fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$42.25b |
| Inkomsten(TTM) | US$1.42b |
| Inkomsten(TTM) | US$15.16b |
29.1x
Koers/Winstverhouding2.7x
P/S-verhoudingIs IQV overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IQV resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$15.16b |
| Kosten van inkomsten | US$9.84b |
| Brutowinst | US$5.32b |
| Overige uitgaven | US$3.90b |
| Inkomsten | US$1.42b |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 7.81 |
| Brutomarge | 35.10% |
| Nettowinstmarge | 9.39% |
| Schuld/Eigen Vermogen Verhouding | 197.6% |
Hoe presteerde IQV op de lange termijn?
Bekijk historische prestaties en vergelijking